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Summary
Background Although several disease-modifying treatments are available for relapsing multiple sclerosis, treatment 
effects have been more modest in progressive multiple sclerosis and have been observed particularly in actively 
relapsing subgroups or those with lesion activity on imaging. We sought to assess whether natalizumab slows disease 
progression in secondary progressive multiple sclerosis, independent of relapses.
Methods ASCEND was a phase 3, randomised, double-blind, placebo-controlled trial (part 1) with an optional 2 year 
open-label extension (part 2). Enrolled patients aged 18–58 years were natalizumab-naive and had secondary 
progressive multiple sclerosis for 2 years or more, disability progression unrelated to relapses in the previous year, 
and Expanded Disability Status Scale (EDSS) scores of 3·0–6·5. In part 1, patients from 163 sites in 17 countries were 
randomly assigned (1:1) to receive 300 mg intravenous natalizumab or placebo every 4 weeks for 2 years. Patients 
were stratified by site and by EDSS score (3·0–5·5 vs 6·0–6·5). Patients completing part 1 could enrol in part 2, in 
which all patients received natalizumab every 4 weeks until the end of the study. Throughout both parts, patients and 
staff were masked to the treatment received in part 1. The primary outcome in part 1 was the proportion of patients 
with sustained disability progression, assessed by one or more of three measures: the EDSS, Timed 25-Foot Walk 
(T25FW), and 9-Hole Peg Test (9HPT). The primary outcome in part 2 was the incidence of adverse events and 
serious adverse events. Efficacy and safety analyses were done in the intention-to-treat population. This trial is 
registered with ClinicalTrials.gov, number NCT01416181.
Findings Between Sept 13, 2011, and July 16, 2015, 889 patients were randomly assigned (n=440 to the natalizumab 
group, n=449 to the placebo group). In part 1, 195 (44%) of 439 natalizumab-treated patients and 214 (48%) of 
448 placebo-treated patients had confirmed disability progression (odds ratio [OR] 0·86; 95% CI 0·66–1·13; 
p=0·287). No treatment effect was observed on the EDSS (OR 1·06, 95% CI 0·74–1·53; nominal p=0·753) or the 
T25FW (0·98, 0·74–1·30; nominal p=0·914) components of the primary outcome. However, natalizumab treatment 
reduced 9HPT progression (OR 0·56, 95% CI 0·40–0·80; nominal p=0·001). In part 1, 100 (22%) placebo-treated 
and 90 (20%) natalizumab-treated patients had serious adverse events. In part 2, 291 natalizumab-continuing 
patients and 274 natalizumab-naive patients received natalizumab (median follow-up 160 weeks [range 108–221]). 
Serious adverse events occurred in 39 (13%) patients continuing natalizumab and in 24 (9%) patients initiating 
natalizumab. Two deaths occurred in part 1, neither of which was considered related to study treatment. No 
progressive multifocal leukoencephalopathy occurred.
Interpretation Natalizumab treatment for secondary progressive multiple sclerosis did not reduce progression on the 
primary multicomponent disability endpoint in part 1, but it did reduce progression on its upper-limb component. 
Longer-term trials are needed to assess whether treatment of secondary progressive multiple sclerosis might produce 
benefits on additional disability components.
Funding Biogen.
Introduction
Patients with multiple sclerosis usually present with 
neurological relapses and the disorder evolves to 
accumulate gradual disability with or without super­
imposed relapses in the secondary progressive phase.1 
Disease­modifying treatments are increasingly available 
for relapsing multiple sclerosis; however, despite 
numerous studies,2–12 benefits in trials of progressive 
multiple sclerosis are modest and mostly target actively 
relapsing subgroups or those with lesion activity on 
imaging. Although recent results have suggested a 
treatment effect of siponimod in secondary progressive 
multiple scleroisis,13 only mitoxantrone has received 
approval for delaying disability in secondary progressive 
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multiple sclerosis, and its use is restricted by substantial 
risks of cardiotoxicity and leukaemia. Hence, an 
important unmet need exists for therapies in secondary 
progressive multiple sclerosis that prevent disability 
progression unrelated to relapse.
Treatments for relapsing multiple sclerosis generally act 
on the peripheral immune response.14 Their limited 
effects on progressive disability suggest that the 
mechanisms of tissue injury are diverse in progressive 
multiple sclerosis. Particular interest has emerged in the 
intrathecal immune response, which is shielded from 
peripherally acting agents behind the blood–brain barrier.14 
Natalizumab, a recombinant humanised monoclonal 
antibody against α4 integrin (very late antigen­4), is highly 
effective in relapsing­remitting multiple sclerosis15 and 
appears to suppress intrathecal inflammation.14 
Natalizumab inhibits leucocyte transmigration across the 
blood–brain barrier, interferes with chemokine­mediated 
inflammatory­cell recruitment into the CNS, and disrupts 
the production of molecules required to sustain intrathecal 
inflammation.16–18 Results from early phase trials in 
progressive multiple sclerosis show that natalizumab 
treatment suppresses CSF markers of inflammation and 
neurodegeneration, including concentrations of osteo­
pontin and the B­cell chemokine CXCL13,14 and suggest 
that treatment also improves ambulation and upper­limb 
function.19–21
On the basis of these considerations, we aimed to 
investigate whether treatment with natalizumab is safe 
and slows the accumulation of disability unrelated to 
relapse in patients with secondary progressive multiple 
sclerosis.
Methods
Study design
The ASCEND study was an international, multicentre, 
phase 3 clinical trial done in two parts. In the randomised, 
double­blind, parallel­group, placebo­controlled phase 
Research in context
Evidence before this study
We searched PubMed for English language articles published 
from Jan 1, 1970, to Sept 1, 2017, using the keyword “secondary 
progressive multiple sclerosis”, on clinical trials of disease-
modifying treatments in secondary progressive multiple sclerosis 
and studies of natalizumab and relevant outcome measures. All 
clinical trials were included. Despite numerous trials, positive 
treatment effects on disability progression were noted only in 
phase 2 trials of simvastatin and methotrexate and in phase 3 
trials of interferon beta-1b and mitoxantrone. Positive results on 
disability progression in a phase 3 trial of siponimod were 
recently presented in a conference abstract. In a phase 2 
proof-of-concept study of natalizumab in progressive forms of 
multiple sclerosis, treatment reduced markers of intrathecal 
inflammation and tissue damage, suggesting that natalizumab 
might have therapeutic efficacy in progressive forms of multiple 
sclerosis. Retrospective analysis of outcomes in two early-phase 
studies of natalizumab in secondary progressive multiple sclerosis 
indicated non-significant improvement in ambulation. For 
assessment of treatment effects in progressive multiple sclerosis, 
the Expanded Disability Status Scale (EDSS) was found to have 
poor responsiveness in patients with high baseline disability 
scores, and detection of disability progression in secondary 
progressive multiple sclerosis was improved with a 
multicomponent endpoint consisting of the EDSS, the Timed 
25-Foot Walk, and the 9-Hole Peg Test. This multicomponent 
endpoint might represent a better measure to detect disability 
progression in secondary progressive multiple sclerosis by 
providing similar power with approximately half the sample size.
Added value of this study
The ASCEND study is, to our knowledge, the first phase 3 trial 
to assess the efficacy of natalizumab on sustained disability 
progression in mostly non-relapsing patients with secondary 
progressive multiple sclerosis, a population with a high 
unmet need for disease-modifying treatments. The 
multicomponent primary outcome used in our study could 
measure disability progression more sensitively than the EDSS 
alone. Although natalizumab treatment did not affect 
progression of the multicomponent primary outcome in the 
randomised controlled phase of the study, we found evidence 
that the upper-limb component of disability did respond to 
treatment and that beneficial effects on the ambulatory 
components were evident with more prolonged therapy 
(beyond 2 years) in the open-label extension phase, in which 
masking of patients and staff to treatment allocation in the 
placebo-controlled phase was maintained.
Implications of all the available evidence
Although natalizumab did not affect progression of the 
primary disability outcome in the placebo-controlled phase of 
ASCEND, it consistently had a positive effect on progression 
of upper-limb disability in part 1 of the study and in those 
patients who continued to receive the treatment in part 2. 
Results from the open-label extension raise the possibility 
that a positive effect on the ambulatory components of the 
primary disability outcome requires more than 2 years of 
treatment. However, it should be noted that secondary 
outcomes in part 1 did not show a treatment effect and the 
effects observed in part 2 are based on nominal significance. 
Although the mechanisms of the positive effects observed in 
this study require further consideration, they raise important 
issues for trial designs for secondary progressive multiple 
sclerosis: future trials might require treatment phases lasting 
3 years or more, and both investigators and regulators might 
need to anticipate the possibility that benefits could be 
restricted to specific but nevertheless key domains such as 
upper-limb ability.
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(part 1), patients with secondary progressive multiple 
sclerosis from 163 sites in 17 countries received 
natalizumab or placebo and underwent scheduled study 
assessments for up to 96 weeks. The 17 countries were 
Belgium, Canada, the Czech Republic, Denmark, Finland, 
France, Germany, Ireland, Israel, Italy, the Netherlands, 
Poland, Russia, Spain, Sweden, the UK, and the USA.
In the prespecified, optional open­label extension 
phase for safety and efficacy (part 2), all patients who 
completed part 1 could receive natalizumab until the end 
of the study. Patients who did not enrol in part 2 stopped 
blinded study treatment at week 96 and returned to the 
study site for a follow­up visit at week 108. Patients who 
opted to enrol in part 2 continued to receive blinded 
study treatment every 4 weeks between enrolment into 
part 2 (week 96) and the start of open­label treatment at 
week 108. In the protocol, the overall end of the study 
was defined as the last patient’s final visit for collection 
of data in part 2. However, part 2 was terminated by the 
after the results of part 1 were released, before 
completion of year 4 of the study, because a significant 
effect on the primary multicomponent endpoint in part 1 
was not observed. Because of the premature trial 
termination, the efficacy analysis was based on data 
collected up to week 156.
The ASCEND study was done in accordance with the 
Declaration of Helsinki, the International Conference 
on Harmonisation, and good clinical practice 
guidelines. Approval for the study protocol, including 
any amendments, was granted by each centre’s ethics 
committee, and all patients provided written informed 
consent before initiating any study­related activities.
An independent drug safety monitoring committee 
reviewed interim unblinded safety data for part 1 of the 
study. This committee met quarterly to review safety 
data and to advise on changes in study design. This 
committee was also charged with determining whether 
the study should be stopped or amended for reasons 
other than safety.
Participants
Natalizumab­naive patients aged 18–58 years were 
eligible for enrolment in part 1 of the ASCEND study 
if they had onset of secondary progressive multiple 
sclerosis 2 or more years before enrolment, an Expanded 
Disability Status Scale (EDSS) score of 3·0–6·5 
(inclusive), a Multiple Sclerosis Severity Score of 4 or 
more, and disability progression not related to clinical 
relapses during the year before enrolment, as assessed 
by clinical historical findings with a standardised 
form (appendix). Unlike previous secondary progressive 
multiple sclerosis trials that enrolled patients with recent 
clinical relapses,2,10,11 ASCEND excluded patients who had 
a clinical relapse up to 3 months before randomisation 
(to prevent recent relapses from influencing the baseline 
assessment of disability). A full list of part 1 inclusion 
and exclusion criteria is included in the appendix.
For inclusion in part 2, eligible patients were required to 
have participated in part 1 and to have completed all part 1 
examinations and efficacy assessments before receiving 
the first open­label dose at week 108 in part 2. Patients 
were excluded from part 2 if they had discontinued study 
treatment, received less than 20 infusions, or missed two 
or more consecutive infusions in part 1.
Randomisation and masking
In part 1 of ASCEND, eligible patients were randomly 
assigned (1:1) to receive natalizumab or placebo of 
identical appearance. Patients were stratified by site and 
by EDSS score (3·0–5·5 vs 6·0–6·5). Patients and study 
staff were masked to treatment assignments in part 1, 
and patients enrolling in part 2 also received blinded 
study treatment during weeks 100 and 104. Patients in 
part 2 received open­label treatment starting in week 108. 
Both patients and study staff remained masked to the 
treatment assignments in part 2. Only the pharmacists 
preparing the infusion and the pharmacy study monitors 
were not masked to the study treatment, which was 
stored in a secure location and accounted for by the 
investigator. Patients were randomly assigned by an 
interactive voice/web response system (IXRS, Bracket 
Global LLC, San Francisco, CA, USA).
Procedures
In part 1, patients received 300 mg intravenous 
natalizumab or placebo every 4 weeks for 2 years. In the 
open­label extension phase in part 2, all patients received 
300 mg intravenous natalizumab every 4 weeks until the 
end of the study. In part 1, EDSS, Timed 25­Foot Walk 
(T25FW), and 9­Hole Peg Test (9HPT) assessments were 
done at baseline and every 12 weeks up to week 108. 
Additional details of T25FW, 9HPT, and MRI assessments 
are provided in the appendix. During part 2, EDSS, 
T25FW, and 9HPT assessments were done at week 156. 
The last progression events that could be confirmed in 
part 1 started at week 84, with final confirmation at 
week 108 (appendix). The additional progression events 
ascertained in part 2 were possible progression starting 
at weeks 96 and 108, when patients who entered part 2 
were still being treated with their blinded therapy 
assignments from part 1. Because of the premature trial 
termination, events at weeks 96 and 108 were confirmed 
at week 156 for patients in part 2, during which all 
patients were treated with open­label natalizumab.
Patients underwent a blood test for presence of anti­JC 
virus (JCV) antibodies at baseline and every 24 weeks 
during parts 1 and 2. As per the study protocol, the 
principal investigator received anti­JCV antibody results 
throughout the study. Investigators were informed of a 
patient’s anti­JCV antibody status before enrolment in 
part 2 and at 24 week intervals thereafter.
Treatment­emergent adverse events and serious adverse 
events were recorded in the safety population during parts 1 
and 2. Over the course of parts 1 and 2 (every 12 weeks up 
See Online for appendix
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to week 108 and at week 156), the treating neurologist 
completed the equivalent of a regular clinic visit. An 
independent neurology evaluation committee (INEC) 
confirmed whether patients had a protocol­defined 
relapse. All reviews were done without knowledge of the 
patient’s treatment assignment and without an MRI scan.
Outcomes
The primary outcome in part 1 was based on a 
multicomponent measure of sustained disability 
progression comprising the EDSS, T25FW, and 9HPT, 
and was designed to provide a more sensitive and specific 
measure of disease worsening in secondary progressive 
multiple sclerosis than EDSS alone.22 The primary 
endpoint was the proportion of patients with confirmed 
disability progression over the 96 week treatment period, 
with progression defined as meeting one or more of the 
following three criteria: an increase of 1·0 points or more 
from a baseline score of 5·5 or lower or an increase of 
0·5 points or more from a baseline score of 6·0 or higher 
on the EDSS; an increase of 20% or more from baseline 
on the T25FW; or an increase of 20% or more from 
baseline (on either hand) on the 9HPT. Progression was 
confirmed at a subsequent visit 6 or more months after 
the start of a possible progression and at the end of the 
trial. To minimise the possibility of capturing disability 
progression due to clinical relapses, included disability 
progression events could not start or be confirmed 74 or 
fewer days following onset of an INEC­confirmed clinical 
relapse. The primary endpoint in part 2 was the incidence 
of adverse events and serious adverse events in patients 
with secondary progressive multiple sclerosis.
In part 1, secondary endpoints included the proportion 
of patients with consistent improvement in T25FW, 
change in patient­reported ambulatory status as measured 
by the 12­item Multiple Sclerosis Walking Scale 
(MSWS­12), change in patient­reported manual ability 
based on the ABILHAND questionnaire,23 the effect of 
natalizumab on patient­reported quality of life with the 
Multiple Sclerosis Impact Scale­29 (MSIS­29) physical 
score, change in whole brain volume between week 24 
and week 96, and the proportion of patients with disability 
progression measured by individual physical EDSS 
functional system scores. Part 2 secondary endpoints 
included the proportion of patients with disability 
progression on the multicomponent endpoint confirmed 
during the additional follow­up time in part 2; change in 
T25FW, 9HPT, and EDSS from part 1 baseline to week 156; 
change in whole brain volume from part 1 week 24 to 
week 156; change in grey matter brain volume from part 1 
baseline to week 156; change in number of T2 lesions 
from part 1 baseline to week 156; change in 6­Minute 
Walk Test, MSIS­29 Physical, and Symbol Digit Modalities 
Test (SDMT) scores from part 1 baseline to week 156; and 
change in Work Productivity and Activity Impairment 
Questionnaire score for multiple sclerosis from part 2 
baseline (week 96) to week 156.
For the SDMT, confirmed progressors were defined 
as those showing a decrease of 4 points or more from 
part 1 baseline. Change from baseline over time for 
T25FW and 9HPT (each hand) was assessed for 
Figure 1: Trial profile
*One patient diagnosed with lung cancer (unrelated to study treatment) discontinued because of this serious 
adverse event. Follow-up revealed that this serious adverse event resulted in death after discontinuation. †One 
patient received the first dose of treatment at week 28 and was therefore not included in the part 1 intention-to-
treat population. ‡Death of one patient, due to septic shock with multiple organ failure (unrelated to study 
treatment), occurred after completion of 96 weeks of treatment but before completion of 108 weeks in the study. 
§Part 2 was terminated by the funder after the results of part 1 were released. ¶At week 156, progression was 
confirmed for weeks 96 and 108 in 209 patients. 
1277 patients assessed for eligibility 
 in part 1
388 excluded
 385 did not meet inclusion criteria
 3 excluded for other reasons
889 randomly assigned in part 1
449 allocated to placebo in part 1 440 allocated to natalizumab in part 1
130 discontinued study drug
 21 adverse events
 25 inadequate efficacy
 1 lost to follow-up
 61 withdrew consent
 7 investigator decision
 15 other
103 discontinued study drug
 21 adverse events (1 death*)
 11 inadequate efficacy
 1 lost to follow-up
 38 withdrew consent
 5 investigator decision
 27 other
319 completed week 96 336 completed week 96
38 excluded or chose not to 
 participate
34 excluded or chose not to 
 participate
274 entered into part 2§
 274 dosed in part 2
 98 progression confirmed¶
292 entered into part 2§
 291 dosed in part 2
 111 progression confirmed¶
1 patient withdrew before 
 receiving natalizumab
312 completed week 108, and were 
 eligible to enter part 2
326 completed week 108, and were 
 eligible to enter part 2
448 included in part 1 intention-
 to-treat analysis
 1 excluded†
439 included in part 1 intention-
 to-treat analysis
7 withdrew before completing 
 week 108
10 withdrew before completing 
 week 108 (1 death‡)
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confirmed T25FW/9HPT progressors versus non­
progressors. Add itionally, a sensitivity analysis of 
confirmed progression on T25FW at thresholds other 
than 20% (25%, 30%, 40%, and 50%) was done. 
Annualised relapse rate (ARR) was assessed, as was 
change from baseline over time for gadolinium­
enhancing (Gd+) lesions. The number and volume of 
new and enlarging T2 lesions were assessed throughout 
the study. Finally, disability outcomes were assessed for 
subgroups with or without baseline Gd+ lesions and 
relapses in the 1–2 years before entering the study.
Statistical analysis
Baseline data were described with summary statistics. 
Treatment comparisons for efficacy endpoints were 
assessed with two­sided tests at a significance level of 0·05. 
A closed testing procedure was used to adjust for multiple 
secondary endpoints. All part 1 efficacy analyses were done 
in the part 1 intention­to­treat population, defined as all 
randomly assigned patients treated at baseline. The part 2 
intention­to­treat population comprised all patients who 
were randomly assigned in part 1 and received one or more 
infusions of the study treatment in part 2. The primary 
endpoint of the percentage of patients with confirmed 
progression was analysed by use of logistic regression with 
baseline EDSS (≤5·5 or ≥6·0), T25FW, and 9HPT of each 
hand as covariates. A sensitivity analysis of the primary 
endpoint based on time to confirmed progression was 
done with a Cox proportional­hazards model with baseline 
EDSS (≤5·5 or ≥6·0), T25FW, and 9HPT of each hand as 
covariates. Time to confirmed progression was defined as 
the time from the first infusion of study treatment to the 
first onset of possible progression that was subsequently 
confirmed. For secondary and exploratory endpoints, 
analysis of covariance and mixed­effects models for 
repeated measures were used to analyse continuous 
outcomes, with baseline measurement and baseline EDSS 
(≤5·5 or ≥6·0) as covariates, and logistic regression was 
used for dichotomous outcomes. For all exploratory 
analyses, all p values cited should be considered nominal 
unless otherwise stated.
The sample size was based on an assumed rate of 
confirmed disability progression over the 2 year period of 
28% for the natalizumab group versus 40% for the 
placebo group—a 30% reduction. We estimated that 
856 patients (428 per group) would provide 90% power at 
the 0·05 level of significance with a two­sided χ² test, 
assuming a 20% dropout rate during the study.
This trial is registered with ClinicalTrials.gov, number 
NCT01416181.
Role of the funding source
The funder initiated and provided funding for this study 
and drafted and provided medical writing and editorial 
support in the development of this manuscript. The 
funder was also involved in study design, data collection, 
data analysis, and data interpretation, and reviewed and 
provided feedback on this manuscript. The authors, 
who include both employees of the funder and academic 
investigators, had full editorial control of this manuscript 
and provided final approval of all content. The 
corresponding author had full access to the study data and 
Part 1 Part 2
Placebo 
(n=448)
Natalizumab 300 mg 
(n=439)
Initiating natalizumab 
(n=274)
Continuing natalizumab 
(n=291)
Age, years 47·2 (7·8)  47·3 (7·4) 47·5 (7·5) 47·2 (7·3)
Women 280 (63%) 270 (62%) 177 (65%) 180 (62%)
Men 168 (37%) 169 (38%) 97 (35%) 111 (38%)
Years since first multiple sclerosis symptoms 16·2 (7·8) 16·8 (7·6) 16·5 (7·9) 16·6 (7·4)
Years since secondary progressive multiple 
sclerosis diagnosis
4·9 (3·7) 4·7 (3·0) 4·6 (3·3) 4·8 (2·9)
Years since most recent relapse before study 4·8 (4·4)* 4·7 (4·1)* 4·8 (4·4) 4·8 (4·3)
Median EDSS score 6·0 (5·0–6·5) 6·0 (5·0–6·5) 6·0 (5·0–6·5) 6·0 (5·0–6·5)
Patients with EDSS score of 3·0–5·5 166 (37%) 165 (38%) 108 (39%) 111 (38%)
Patients with EDSS score of 6·0–6·5 282 (63%) 274 (62%) 166 (61%) 180 (62%)
Median T25FW, s 11·2 (7·9–16·8) 11·2 (7·9–17·5) 11·1 (7·6–17·0) 11·0 (7·8–16·7)
Median 9HPT, s
Dominant hand 28·8 (23·8–36·6) 28·2 (23·5–36·4) 28·6 (23·2–36·7) 27·8 (23·6–36·4)
Non-dominant hand 29·6 (24·7–40·2) 29·6 (25·0–38·5) 29·5 (24·1–40·8) 29·5 (24·8–39·0)
Patients with Gd+ lesions 96 (22%)† 114 (26%)† 54 (20%) 77 (26%)
T2 lesion volume, cm³ 16·2 (16·4)‡ 17·4 (17·6)‡ 16·3 (16·4) 17·7 (18·5)
Normalised whole brain volume, cm³ 1425·8 (83·1)§ 1420·9 (82·8)§ 1431·2 (82·0) 1425·3 (80·3)
Data are n (%), mean (SD), or median (IQR). EDSS=Expanded Disability Status Scale. Gd+=gadolinium enhancing. T25FW=Timed 25-Foot Walk. 9HPT=9-Hole Peg Test. *n=430 
for placebo; n=431 for natalizumab. †n=446 for placebo; n=438 for natalizumab. ‡n=447 for placebo; n=437 for natalizumab. §n=444 for placebo; n=436 for natalizumab.
Table 1: Baseline clinical characteristics of the intention-to-treat population
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had final responsibility for the decision to submit for 
publication.
Results
Between Sept 13, 2011, and July 16, 2015, 889 patients were 
randomly assigned in part 1, and 888 patients received at 
least one infusion of the study drug (natalizumab, n=439; 
placebo, n=449; figure 1). 887 patients were included in the 
part 1 intention­to­treat population (natalizumab, n=439; 
placebo, n=448). One placebo­treated patient received the 
first dose at week 28 and was therefore not included in the 
part 1 intention­to­treat population. 655 (74%) patients 
(natalizumab, n=336; placebo, n=319) completed 
treatment through to week 96, and 638 (72%) patients 
(natalizumab, n=326; placebo, n=312) completed the study 
through to the end of part 1 (week 108). Following part 1, 
566 patients continued into part 2 (continuing 
natalizumab, n=292; initiating natalizumab, n=274), and 
565 patients received the study drug and were included in 
the part 2 intention­to­treat population (continuing 
natalizumab, n=291; initiating natalizumab, n=274). In 
part 2, the first treatment was received on Dec 2, 2013, and 
the study ended on April 13, 2016. The median total follow­
up time, including the 96 weeks of part 1, was 157 weeks 
(range 108–221) for patients initiating natalizumab 
(switching from placebo) and 160 weeks (118–213) for 
patients continuing natalizumab.
At baseline for part 1, clinical characteristics were 
balanced between treatment groups. Characteristics were 
also balanced between patients from part 1 and those who 
enrolled into part 2 (table 1). Baseline characteristics were 
generally similar between patients in the ASCEND part 1 
intention­to­treat population who entered part 2 and those 
who did not (appendix). In the part 1 intention­to­treat 
population (n=887), the mean time since first multiple 
sclerosis symptoms was 16·5 (SD 7·7) years. At baseline, 
ambulatory impairment was present in all patients and 
was advanced in the majority; 556 (63%) patients had 
EDSS scores of 6·0–6·5 (requiring walking aid) and only 
13 (1%) patients had an EDSS score of 3·0 (n=7 for 
natalizumab, n=6 for placebo). The overall mean baseline 
EDSS score was 5·6 (SD 0·9). As intended by the study 
design, enrolled patients with secondary progressive 
multiple sclerosis had minor relapse activity; 744 (84%) 
were relapse­free within the year before baseline 
assessment (n=373 for the natalizumab group, n=371 for 
the placebo group) and 627 (71%) were relapse­free within 
the 2 years before baseline assessment (n=312 for the 
natalizumab group, n=315 for the placebo group). 
ASCEND did not meet the primary endpoint for part 1 
assessed at 2 years (figure 2). The proportion of confirmed 
progressors on the primary endpoint was lower in the 
natalizumab group (195 [44%] of 439) than in the placebo 
group (214 [48%] of 448), but the difference was not 
significant (p=0·287). No treatment effect was observed 
on two components of the primary endpoint that 
measure progression of ambulatory disability: EDSS and 
T25FW (figure 2). However, natalizumab treatment was 
associated with a nominally significant 44% reduction in 
the relative risk of confirmed upper­limb disability 
progression as measured by 9HPT, the third component 
of the primary endpoint (64 [15%] with natalizumab vs 
104 [23%] with placebo; adjusted odds ratio [OR] 0·56 
[95% CI 0·40–0·80]; p=0·001; figure 2).
In part 1, no significant differences between treatment 
groups in the change from baseline to year 2 were seen in 
any of the secondary endpoints, including MSWS­12, 
ABILHAND, and MSIS­29 (appendix). From week 24 to 
week 96 in part 1, the mean percentage change in whole 
brain volume was −0·66% (SD 0·60) in natalizumab­
treated patients and −0·72% (0·66) in placebo­treated 
patients (p=0·242).
Exploratory analyses suggested that the effect of 
natalizumab on slowing upper­limb disability accumu­
lation as measured by 9HPT in part 1 was observed 
regardless of baseline Gd+ lesions and was apparent in 
patients without relapses in the 1–2 years before the study 
(appendix), although differences between subgroups 
were not significant.
In additional exploratory analyses, natalizumab 
improved the ARR and outcomes of MRI endpoints 
compared with placebo (appendix).
In part 1, 410 (91%) patients in the placebo group and 
401 (91%) in the natalizumab group reported one or more 
Figure 2: Proportion of patients with confirmed disability progression in the randomised, double-blind, 
placebo-controlled phase (part 1) and the open-label extension (part 2) 
(A) Patients who entered the ASCEND study who showed confirmed disability progression over 96 weeks (part 1 
intention-to-treat population). (B) Patients who entered the open-label extension of the ASCEND study who 
showed confirmed progression over 108 weeks, with confirmation up to 156 weeks (part 2 intention-to-treat 
population). OR=odds ratio. 9HPT=9-Hole Peg Test. T25FW=Timed 25-Foot Walk. EDSS=Expanded Disability 
Status Scale. *Primary endpoint. †Either hand.
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adverse events (table 2). Overall, adverse events were 
similar between natalizumab­treated and placebo­treated 
patients in part 1 (table 2). Natalizumab was generally 
well tolerated, with observed adverse events consistent 
with the known safety profile of natalizumab at the 
approved dose (300 mg every 4 weeks).15 Table 3 shows all 
serious adverse events occurring in 1% or more patients 
in both treatment groups; all serious adverse events 
occurring in one or more patients are reported in the 
appendix. In part 1, the proportion of patients reporting a 
serious adverse event was similar for the two treatment 
groups (90 [20%] for natalizumab vs 100 [22%] for 
placebo; table 3). Multiple sclerosis relapse was the most 
frequently reported serious adverse event in the two 
treatment groups, occurring in 21 (5%) patients in the 
natalizumab group versus 28 (6%) in the placebo group. 
The only other serious adverse events reported in 1% or 
more patients in either treatment group were urinary 
tract infection (five [1%] in the natalizumab group vs 12 
[3%] in the placebo group), fall (six [1%] vs three [<1%]), 
and pneumonia (two [<1%] vs five [1%]; table 3). During 
the course of part 1, two patients receiving natalizumab 
died: one of lung cancer, and the other of septic shock 
with multiple organ failure. The investigators assessed 
both events to be unrelated to study treatment.
For the part 2 primary endpoint, 245 (84%) patients 
continuing natalizumab and 250 (91%) initiating 
natalizumab reported one or more adverse events (table 2). 
Adverse events were generally similar among patients 
continuing natalizumab and those initiating natalizumab 
in part 2 (table 2). No deaths occurred in part 2, and 
serious adverse events were reported by 39 (13%) patients 
continuing natalizumab and 24 (9%) initiating 
natalizumab (table 3). As in part 1, multiple sclerosis 
relapse was the most frequently reported serious adverse 
event, occurring in five (2%) patients in each group. No 
cases of progressive multifocal leukoencephalopathy 
occurred in part 1 or 2, and no new safety concerns were 
identified during the course of the study.
For secondary efficacy analyses in part 2, the 
proportion of patients who progressed on the multi­
component endpoint was lower in the natalizumab­
treated group than in the placebo­treated group (150 [52%] 
vs 167 [61%]; adjusted OR 0·67 [95% CI 0·47–0·94]; 
p=0·021; figure 2). As in part 1, upper­limb progression 
assessed by 9HPT in part 2 was lower in patients 
continuing natalizumab than in those initiating 
natalizumab (55 [19%] vs 78 [28%]; adjusted OR 0·59 
[95% CI 0·39–0·88]; p=0·009; figure 2). All other 
secondary endpoints in part 2 did not show a treatment 
effect. An exploratory analysis done with Kaplan­Meier 
estimates of the cumulative probability, over 156 weeks, of 
time to confirmed progression on the multicomponent 
endpoint (including the total part 1 intention­to­treat 
population, with data from patients who did not enrol in 
part 2 censored at week 108) showed significantly 
increased separation over time between patients originally 
Part 1 Part 2
Placebo 
(n=449)
Natalizumab 
300 mg 
(n=439)
Initiating 
natalizumab 
(n=274)
Continuing 
natalizumab 
(n=291)
Patients with one or more events 410 (91%) 401 (91%) 250 (91%) 245 (84%)
Events occurring in 10% or more patients in any group
Urinary tract infection 107 (24%) 102 (23%) 56 (20%) 53 (18%)
Nasopharyngitis 73 (16%) 98 (22%) 39 (14%) 47 (16%)
Fall 86 (19%) 87 (20%) 38 (14%) 44 (15%)
Multiple sclerosis relapse 122 (27%) 73 (17%) 34 (12%) 27 (9%)
Headache 50 (11%) 66 (15%) 17 (6%) 26 (9%)
Fatigue 53 (12%) 59 (13%) 35 (13%) 33 (11%)
Upper respiratory tract infection 30 (7%) 48 (11%) 11 (4%) 10 (3%)
Back pain 51 (11%) 46 (10%) 41 (15%) 35 (12%)
Arthralgia 40 (9%) 43 (10%) 26 (9%) 20 (7%)
Pain in hands and feet 42 (9%) 42 (10%) 28 (10%) 28 (10%)
Muscular weakness 39 (9%) 28 (6%) 31 (11%) 15 (5%)
Table 2: Treatment-emergent adverse events occurring in the safety population of part 1 and part 2
Part 1 Part 2
Placebo
(n=449)
Natalizumab 
(n=439)
Initiating 
natalizumab 
(n=274)
Continuing 
natalizumab
(n=291)
Patients with one or more events 100 (22%) 90 (20%) 24 (9%) 39 (13%)
Events occurring in 1% or more patients in any group
Multiple sclerosis relapse 28 (6%) 21 (5%) 5 (2%) 5 (2%)
Urinary tract infection 12 (3%) 5 (1%) 1 (<1%) 4 (1%)
Pneumonia 5 (1%) 2 (<1%) 1 (<1%) 0
Multiple sclerosis 5 (1%) 0 0 0
Fall 3 (<1%) 6 (1%) 1 (<1%) 1 (<1%)
Urosepsis 1 (<1%) 3 (<1%) 1 (<1%) 4 (1%)
Table 3: Treatment-emergent serious adverse events in the safety population in part 1 and part 2
Figure 3: Time to confirmed disability progression on the multicomponent endpoint in parts 1 and 2
The part 1 intention-to-treat population contributed progression data over 84 weeks, and the part 2 
intention-to-treat population additionally contributed progression data at weeks 96 and 108. *Includes patients 
taking placebo in part 1 and patients initiating natalizumab in part 2. HR=hazard ratio.
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randomly assigned to natalizumab and those randomly 
assigned to placebo who initiated natalizumab at week 108 
(52·1% vs 64·2%; p=0·010; figure 3).
MRI endpoints based on focal inflammation in part 2 
are shown in the appendix. During part 2, the risk of 
relapse was 39·3% lower for patients continuing 
natalizumab than for those initiating natalizumab (ARR 
0·11 vs 0·19; rate ratio 0·607 [95% CI 0·424–0·868]; 
p=0·006).
Discussion
During the 2 year randomised treatment stage (part 1) of 
this phase 3 clinical trial, natalizumab did not 
significantly reduce disability progression as assessed by 
the primary multicomponent endpoint and secondary 
endpoints in patients with secondary progressive 
multiple sclerosis. However, progression of the upper­
limb component of the primary disability endpoint, as 
assessed by 9HPT, was reduced in both parts 1 and 2. 
Significant efficacy was also observed on reductions in 
ARR and MRI measures of focal inflammation, as 
expected from previous trials in patients with relapsing­
remitting multiple sclerosis.15 Imaging studies showed 
that treatment did not affect loss of whole brain volume 
during part 1, but that whole brain volume loss was 
significantly lower when considering parts 1 and 2 
together or part 2 separately.
Interpretation of the positive treatment effects in part 2 
is limited by the fact that this was an open­label extension 
phase of ASCEND and that the study was not designed 
with part 1 as an interim analysis. Significance was not 
achieved on the primary endpoint during part 1; 
therefore, significance in part 2 is only nominal, 
since adjustments for multiplicity were not applied. 
Furthermore, because of early termination, part 2 did not 
last for the planned 2 years beyond the end of part 1. This 
early closure might have precluded detection of outcomes 
requiring a longer period of time to show a treatment 
effect. It should also be noted that, for part 1, disability 
progression was required to be confirmed not only at a 
visit 6 or more months later, with the period of 3 months 
following onset of an adjudicated clinical relapse 
excluded, but also at week 96. This is possibly the most 
stringent requirement for verification of progression 
adopted for progressive multiple sclerosis trials to date. 
During part 1, the attrition rate was somewhat higher 
than expected (638 [72%] of 888 patients completed 
108 weeks, so the dropout rate [28%] was higher than the 
predicted dropout of 20%). However, the numbers of 
patients in each treatment group who completed the 
study were similar (n=326 for natalizumab vs n=312 for 
placebo). Additionally, it was prespecified that possible 
disability progression for patients who discontinued 
could be confirmed on the basis of the discontinuation 
visit measurements, and progression could also be 
considered confirmed if patients discontinued treatment 
because of inadequate efficacy (at the discretion of the 
investigator). The effect of attrition on the validity of the 
conclusions is therefore limited. Patients in part 2 were a 
subset of the original randomised population, and 
disability measurements for those not continuing to 
part 2 were incomplete because of early termination of 
that phase of the trial, so selection bias could have 
occurred. However, patients who did or did not enter the 
open­label extension had similar baseline characteristics 
and disability progression out comes in part 1, suggesting 
that selection bias was minimal. Bias was limited further 
by maintaining full masking to the initial treatment 
allocation through the open­label extension. Masking 
was also maintained for the imaging measurements, 
although bias might have occurred because of 
pseudoatrophy affecting whole brain matter volume in 
patients newly initiating natalizumab in part 2.
In contrast to several previous trials in secondary 
progressive multiple sclerosis,2,10,11 ASCEND enrolled 
patients with predominantly non­relapsing secondary 
progressive multiple sclerosis, who constitute a multiple 
sclerosis population with high unmet needs. Furthermore, 
at baseline, the majority of ASCEND patients had 
advanced disability with ongoing disease progression 
unrelated to relapses: 63% had EDSS scores of 6·0–6·5, 
and 71% had no relapses in the 2 years before baseline 
assessment. The on­study ARR in patients randomly 
assigned to placebo was low (0·17 [95% CI 0·14–0·21]; 
appendix), further supporting the low relapsing activity of 
the enrolled population. These patients represent the 
secondary progressive multiple sclerosis population for 
whom no effective therapy is available to delay or prevent 
further disability progression unrelated to relapses.
Detecting change with available validated outcome 
measures in a slowly progressing multiple sclerosis 
population over a short period of observation is difficult. 
The multicomponent endpoint used in this study might 
be more sensitive to changes in disability than the EDSS 
alone,22 but two of its three components focus on lower­
limb function and were not affected by treatment. The 
EDSS, in particular, has been shown to have poor 
responsiveness to disease progression and treatment 
effects in patients with high baseline scores.21 Other 
studies in patients with secondary progressive multiple 
sclerosis have used composite outcome measurements 
and reported differences in outcomes assessing upper­
limb versus lower­limb function,11,24 highlighting the 
importance of using sensitive measures of disease 
worsening in secondary progressive multiple sclerosis 
trials that include key domains of function in addition to 
ambulation.25
In part 1 of this study, we observed an apparent 
beneficial effect of natalizumab on limb function but not 
on measures of ambulation. Although this difference 
could be explained by different treatment effects on 
neural systems serving different functions, the findings 
are also consistent with the possibility that the benefits of 
stopping inflammation from further damaging the CNS 
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manifest after a delay that is shorter in pathways with 
shorter axons than in pathways with longer axons.26 
Axons undergoing injury might continue to degenerate 
even after the mechanisms of injury are inhibited by 
treatment (eg, from trans­synaptic degeneration or 
because demyelination renders them vulnerable to 
injury). Delayed clinical and imaging responses have 
been observed in trials of interferon beta and 
natalizumab,26–28 and are apparent in the results of the 
open­label phase of the ASCEND trial. Residual 
degeneration should abate more quickly in shorter axon 
pathways than in longer ones because shorter axons have 
a lower lesion burden. If the resulting length­dependent 
therapeutic lag does exist, future trial designs might 
need to consider longer treatment phases to capture 
benefits in all key aspects of disability and to plan for 
domain­specific outcome measures, which will respond 
at successively later stages in the trial.
In general, the delay in appearance of any treatment 
effects in patients with secondary progressive multiple 
sclerosis differs substantially from the rapid onset of 
the effects of natalizumab in patients with relapsing­
remitting multiple sclerosis,29 suggesting a difference in 
the underlying disease mechanisms of relapsing­
remitting and secondary progressive multiple sclerosis 
with regard to their response to α4 integrin antagonism. 
The observation that the beneficial effects of natalizumab 
on upper­limb disability progression occurred regardless 
of baseline Gd+ lesions or relapses before entry further 
suggests that treatment effects in secondary progressive 
multiple sclerosis might occur through different 
mechanisms to those observed in relapsing­remitting 
multiple sclerosis.
Natalizumab was generally well tolerated throughout 
both parts of ASCEND. No new or unexpected safety 
concerns were associated with its use in a secondary 
progressive multiple sclerosis population, and the 
observed safety profile was consistent with that of 
previous studies of natalizumab in patients with 
relapsing­remitting multiple sclerosis.15 The beneficial 
effects of natalizumab on ARR and on new and active 
brain lesions in ASCEND were also consistent with 
previous findings in patients with relapsing multiple 
sclerosis,15 and with continued anti­inflammatory activity 
in secondary progressive multiple sclerosis.14 However, 
natalizumab is not approved for treatment of patients 
with non­relapsing secondary progressive multiple 
sclerosis, and its benefit–risk profile has only been 
examined for treatment of patients with relapsing forms 
of multiple sclerosis.
The results of the 9HPT analyses consistently suggest 
that natalizumab delays loss of upper­limb function, and 
exploratory analyses suggest that this treatment effect 
occurred independently of active brain lesions (appendix). 
The 20% threshold of change in the 9HPT used in the 
primary endpoint in this study is consistent with that of 
previous work, which indicates that this difference 
corresponds to a clinically meaningful change in upper­
limb function.30 Upper­limb function correlates 
independently with quality of life31 and is a strong 
predictor of treatment costs in multiple sclerosis.32 
Preservation of upper­limb function ranks highly among 
treatment benefits desired by disabled patients with 
multiple sclerosis, in some instances more highly than 
lower­limb function for maintenance of independence. 
Patients also consider that those confined to wheelchairs 
should not be excluded from future clinical trials in 
progressive multiple sclerosis.33 Treatments that can 
preserve ability in a single functional domain could, 
therefore, still be valuable for patients with secondary 
progressive multiple sclerosis in real­world settings.
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